Literature DB >> 20425059

Strategies to achieve target LDL levels.

Alan Chait1.   

Abstract

Year:  2010        PMID： 20425059     DOI： 10.1007/s11892-009-0078-6

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


× No keyword cloud information.
  9 in total

1.  After ENHANCE: is more LDL cholesterol lowering even better?

Authors:  Evan A Stein
Journal:  Clin Chem       Date:  2008-04-10       Impact factor: 8.327

2.  Statin therapy with ezetimibe or niacin in high-risk patients.

Authors:  John J P Kastelein; Michiel L Bots
Journal:  N Engl J Med       Date:  2009-11-15       Impact factor: 91.245

3.  Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia.

Authors:  Gloria Lena Vega; Nilo B Cater; Shinishi Meguro; Scott M Grundy
Journal:  Am J Cardiol       Date:  2005-06-01       Impact factor: 2.778

4.  Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.

Authors:  M B Elam; D B Hunninghake; K B Davis; R Garg; C Johnson; D Egan; J B Kostis; D S Sheps; E A Brinton
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

5.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Authors:  A Keech; R J Simes; P Barter; J Best; R Scott; M R Taskinen; P Forder; A Pillai; T Davis; P Glasziou; P Drury; Y A Kesäniemi; D Sullivan; D Hunt; P Colman; M d'Emden; M Whiting; C Ehnholm; M Laakso
Journal:  Lancet       Date:  2005-11-26       Impact factor: 79.321

6.  Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.

Authors:  Jerome L Fleg; Mihriye Mete; Barbara V Howard; Jason G Umans; Mary J Roman; Robert E Ratner; Angela Silverman; James M Galloway; Jeffrey A Henderson; Matthew R Weir; Charlton Wilson; Mario Stylianou; Wm James Howard
Journal:  J Am Coll Cardiol       Date:  2008-12-16       Impact factor: 24.094

7.  Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).

Authors:  Xue-Qiao Zhao; Josh S Morse; Alice A Dowdy; Nancy Heise; Debbie DeAngelis; Jiri Frohlich; Alan Chait; John J Albers; B Greg Brown
Journal:  Am J Cardiol       Date:  2004-02-01       Impact factor: 2.778

8.  Simvastatin with or without ezetimibe in familial hypercholesterolemia.

Authors:  John J P Kastelein; Fatima Akdim; Erik S G Stroes; Aeilko H Zwinderman; Michiel L Bots; Anton F H Stalenhoef; Frank L J Visseren; Eric J G Sijbrands; Mieke D Trip; Evan A Stein; Daniel Gaudet; Raphael Duivenvoorden; Enrico P Veltri; A David Marais; Eric de Groot
Journal:  N Engl J Med       Date:  2008-03-30       Impact factor: 91.245

9.  Extended-release niacin or ezetimibe and carotid intima-media thickness.

Authors:  Allen J Taylor; Todd C Villines; Eric J Stanek; Patrick J Devine; Len Griffen; Michael Miller; Neil J Weissman; Mark Turco
Journal:  N Engl J Med       Date:  2009-11-15       Impact factor: 91.245
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.